NASDAQ:MREO

Mereo BioPharma Group Stock Forecast, Price & News

$3.18

-0.05 (-1.55 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.17

▼

$3.30

50-Day Range

$2.94

▼

$4.08

52-Week Range

$1.90

▼

$4.71

Volume800,486 shs

Average Volume1.90 million shs

Market Capitalization$215.58 million

P/E RatioN/A

Dividend YieldN/A

Beta1.73

30 days | 90 days | 365 days | Advanced Chart

Receive MREO News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
June 2, 2021 | finance.yahoo.com

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)
June 2, 2021 | finance.yahoo.com

Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
May 27, 2021 | finance.yahoo.com

Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
May 4, 2021 | finance.yahoo.com

Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab
April 30, 2021 | feeds.benzinga.com

Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
April 8, 2021 | finance.yahoo.com

Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 | finance.yahoo.com

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
February 12, 2021 | finance.yahoo.com

Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
November 23, 2020 | benzinga.com

Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
November 16, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MREO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.mereobiopharma.com
Phone44-33-3023-7300
Employees38
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.28) per share
Price / Book-11.36

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares67,791,000
Market Cap$215.58 million
Next Earnings Date6/30/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.18 out of 5 stars

Medical Sector

988th out of 2,096 stocks

Pharmaceutical Preparations Industry

486th out of 830 stocks

3.5 Analyst's Opinion

Consensus Rating
Mereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Mereo BioPharma Group has a forecasted upside of 214.5% from its current price of $3.18.
Amount of Analyst Coverage
Mereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Mereo BioPharma Group has received 16 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mereo BioPharma Group has received 17 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mereo BioPharma Group has received 51.52% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote “Outperform” if you believe MREO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MREO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mereo BioPharma Group does not currently pay a dividend.
Dividend Growth
Mereo BioPharma Group does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Mereo BioPharma Group are expected to decrease in the coming year, from ($0.51) to ($0.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mereo BioPharma Group is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mereo BioPharma Group is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Mereo BioPharma Group (NASDAQ:MREO) Frequently Asked Questions

Is Mereo BioPharma Group a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mereo BioPharma Group stock.
View analyst ratings for Mereo BioPharma Group or view top-rated stocks.

What stocks does MarketBeat like better than Mereo BioPharma Group?

Wall Street analysts have given Mereo BioPharma Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mereo BioPharma Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Mereo BioPharma Group's next earnings date?

Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 30th 2021.
View our earnings forecast for Mereo BioPharma Group.

How has Mereo BioPharma Group's stock been impacted by Coronavirus (COVID-19)?

Mereo BioPharma Group's stock was trading at $1.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MREO shares have increased by 105.2% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MREO?

2 analysts have issued twelve-month price objectives for Mereo BioPharma Group's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Mereo BioPharma Group's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 214.5% from the stock's current price.
View analysts' price targets for Mereo BioPharma Group or view top-rated stocks among Wall Street analysts.

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the following people:

Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 62, Pay $1.23M)
Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 52, Pay $898.21k)
Dr. Alastair MacKinnon MBBS, M.D., Co-Founder and Chief of Portfolio & Pipeline Strategy (Age 51, Pay $885.1k)
Mr. John Richard, Co-Founder & Chief Bus. Officer (Age 64, Pay $838.97k)
Dr. John A. Lewicki, Chief Scientific Officer (Age 69, Pay $793.37k)
Ms. Alexandra Hughes-Wilson, Chief of Patient Access & Commercial Planning (Age 50, Pay $508.3k)
Ms. Jill Henrich, US Site Head & Sr. VP of Regulatory Affairs (Age 58, Pay $430.25k)
Ms. Christine Fox CPA, Chief Financial Officer (Age 40)
Dr. Fiona Bor, Head of Intellectual Property
Mr. Ian Hodgson, Head of Clinical Operations

Who are some of Mereo BioPharma Group's key competitors?

Some companies that are related to Mereo BioPharma Group include ChemoCentryx (CCXI), Silence Therapeutics (SLN), ADVANZ PHARMA (CXRXF), Prometheus Biosciences (RXDX), Collegium Pharmaceutical (COLL), Nkarta (NKTX), Affimed (AFMD), Evelo Biosciences (EVLO), Calliditas Therapeutics AB (publ) (CALT), Praxis Precision Medicines (PRAX), Pharming Group (PHAR), Karyopharm Therapeutics (KPTI), Verastem (VSTM), Xenon Pharmaceuticals (XENE) and Chinook Therapeutics (KDNY).
View all of MREO's competitors.

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?

(MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (25.47%), Point72 Asset Management L.P. (12.21%), Baker BROS. Advisors LP (9.91%), Suvretta Capital Management LLC (9.39%), Perceptive Advisors LLC (8.85%) and Rock Springs Capital Management LP (6.63%).

Which institutional investors are selling Mereo BioPharma Group stock?

MREO stock was sold by a variety of institutional investors in the last quarter, including Holocene Advisors LP, Silverarc Capital Management LLC, Renaissance Technologies LLC, and CSS LLC IL.

Which institutional investors are buying Mereo BioPharma Group stock?

MREO stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Rock Springs Capital Management LP, Suvretta Capital Management LLC, Orbimed Advisors LLC, Millennium Management LLC, Endurant Capital Management LP, and Sphera Funds Management LTD..

How do I buy shares of Mereo BioPharma Group?

Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mereo BioPharma Group's stock price today?

One share of MREO stock can currently be purchased for approximately $3.18.

How much money does Mereo BioPharma Group make?

Mereo BioPharma Group has a market capitalization of $215.58 million. The company earns $-210,100,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does Mereo BioPharma Group have?

Mereo BioPharma Group employs 38 workers across the globe.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is www.mereobiopharma.com.

Where are Mereo BioPharma Group's headquarters?

Mereo BioPharma Group is headquartered at ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company can be reached via phone at 44-33-3023-7300 or via email at [email protected]

This page was last updated on 6/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here